37599-59-0

Basic information

• Product Name: 1H-pyrazol-4-ylmethylamine
• Synonyms: 1H-pyrazol-4-ylmethylamine;1-(1H-PYRAZOL-4-YL)METHANAMINE;ART-CHEM-BB B037991;VITAS-BB TBB002599;(1H-pyrazol-4-yl)methanamine;4-AMinoMethyl-1H-pyrazole;4-(AMinoMethyl)pyrazole;C-(1H-Pyrazol-4-yl)-methylamine
• CAS NO: 37599-59-0
• Molecular Formula: C₄H₇N₃
• Molecular Weight: 97.12
• Mol File: 37599-59-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 284.8±15.0 °C(Predicted)
• Appearance: /
• Density: 1.199±0.06 g/cm3(Predicted)
• PKA: 14.62±0.50(Predicted)
• CAS DataBase Reference: 1H-pyrazol-4-ylmethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-pyrazol-4-ylmethylamine(37599-59-0)
• EPA Substance Registry System: 1H-pyrazol-4-ylmethylamine(37599-59-0)

Safety Data

• Hazardous Substances Data: 37599-59-0(Hazardous Substances Data)

Usage

General Description

1H-pyrazol-4-ylmethylamine is a chemical compound that belongs to the class of organic compounds known as amines. This organic compound exhibits a simple aromatic ring and a primary amine group (-NH2) attached to the molecular structure. It is a derivative of pyrazole, a simple aromatic ring system, where the primary amine group is bonded to one of the carbon atoms of the ring. Although its specific applications and properties may differ, this compound possesses characteristics common to aromatic amines which include basicity and participation in various chemical reactions. Further information regarding its physical properties, potential uses and safety measures would have to be assessed on an individual basis.

Upstream product

• 31108-57-3 1H-pyrazole-4-carbonitrile 

Downstream Products

• 1605327-06-7 (S)-N-((1H-pyrazol-4-yl)methyl)-4-((1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide 
• 1107620-72-3 tert-butyl ((1H-pyrazol-4-yl)methyl)carbamate 

Relevant articles and documents

CANCER TREATMENTS TARGETING CANCER STEM CELLS

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O'), and (I):

COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY

The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.